Advances in Treatment for Lung, Esophageal, and Nasopharyngeal Cancers To Be Presented at the ASCO Breakthrough Meeting in Japan

ALEXANDRIA, Va. - The American Society of Clinical Oncology (ASCO) Breakthrough meeting will bring together practicing clinicians, oncology thought leaders, med-tech pioneers, and research trailblazers to discuss how we can harness the latest innovations in cancer care technology to accelerate progress and improve patient outcomes.

Taking place August 8-10 in Yokohama, Japan and online, ASCO Breakthrough is planned and cohosted by ASCO, the Japan Society of Clinical Oncology, the Japanese Society of Medical Oncology, along with many other collaborating societies in the Asia Pacific region.

More than 220 abstracts will be presented at ASCO Breakthrough. Abstract titles are now available online and the full abstracts will be publicly released on Monday, August 5, at 5:00 PM (ET) at www.asco.org/bkth-abstracts.

ASCO BREAKTHROUGH PRESS PROGRAM

The following research will be highlighted in a press release and virtual press briefing on Sunday, August 4 at 10:00 PM (ET)/Monday, August 5 at 11:00 AM (JST):

• Updated results from a randomized, phase III study conducted in China comparing radiotherapy alone to radiotherapy with concurrent chemotherapy in patients with low-risk nasopharyngeal carcinoma. (Abstract 142)
• Findings from the preSINO cohort trial in Asia evaluating the accuracy of detecting residual disease following neoadjuvant chemotherapy for esophageal squamous cell carcinoma (Abstract 196)
• An East Asian subgroup analysis of the LIBRETTO-431 trial studying the efficacy and safety of first-line selpercatinib in RET fusion-positive non-small cell lung cancer. (Abstract 214)

Reporters must have approved ASCO media credentials in order to participate in the virtual press event. More information about how to obtain media credentials is provided below.

The following studies will be included in the official ASCO Tip Sheet, a brief summary of additional noteworthy research. The Tip Sheet will be sent to credentialed reporters ahead of the meeting and will include additional comments from the lead study authors and outside perspective from ASCO experts.

• PD-1 blockade with camrelizumab after chemoradiotherapy in nasopharyngeal carcinoma. (Abstract 129)
• Efficacy and safety of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in combination with pembrolizumab in patients with KRAS G12C-mutant advanced NSCLC. (Abstract 195)
• The impact of HRD mutation on survival in patients with KRAS-mutated advanced pancreatic cancer: A real-world database study. (Abstract 221)
• Patient-reported outcomes (PROs) from a randomized, phase 3 trial of enfortumab vedotin plus pembrolizumab (EV+P) versus platinum-based chemotherapy (PBC) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC). (Abstract 108)
• Voice-based depression assessment in patients with gynecological cancer. (Abstract 161)
• Intracranial outcomes of 1L selpercatinib in advanced RET fusion-positive NSCLC: LIBRETTO-431 study. (Abstract 199)
• Circulating tumor DNA for predicting radiographic and pathologic response to total neoadjuvant therapy in locally advanced rectal cancer: ENSEMBLE-1. (Abstract 71)
• Updated efficacy of anti-TROP2 ADC ESG401 for first-line metastatic TNBC in phase 1b study. (Abstract 2)
• Effect of heterozygosity loss of HLA-I on immune evasion and promotion of non-small cell lung cancer brain metastasis and immunotherapy resistance. (Abstract 209)
• Surufatinib plus toripalimab in advanced soft tissue sarcoma (STS): Results from a multicenter, single-arm, basket study. (Abstract 42)
• A comprehensive meta-analysis of tissue resident memory T cell shaping non-small-cell lung cancer immune microenvironment and patient prognosis. (Abstract 210)
• Precision medicine-based platform to guide the treatment of EML4-ALK driven lung cancers and other NSCLC in real time. (Abstract 215)
• Prognostic value of immuno-nutritional status in patients with cancer treated by immune checkpoint inhibitors. (Abstract 226)
• Programmed cell death ligand 1 (PD-L1) inhibitors versus programmed cell death 1 (PD-1) inhibitors for the first-line therapy of extensive-stage small cell lung cancer: A propensity score-matched study. (Abstract 206)
• Safety analysis by treatment periods from EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization with durvalumab with/without bevacizumab in participants with embolization-eligible unresectable hepatocellular carcinoma. (Abstract 65)
• First implementation of artificial intelligence empowered all-in-one radiotherapy workflow for nasopharyngeal carcinoma. (Abstract 134)
• Deciphering the prognostic value of FGFR2b/2c isoform expression levels in advanced esophagogastric cancer through whole-transcriptome sequencing. (Abstract 53)

MEDIA RESOURCES

In-person or online-only registration is complimentary for reporters who meet ASCO's requirements for media credentials. In addition, reporters with approved media credentials are able to access the embargoed media materials, session livestreams, and on-demand content.

For more information on how to apply for ASCO media credentials and/or to register for the meeting, please visit the ASCO Breakthrough Media Resource Center.

Please note: If you currently have approved ASCO media credentials, you must RSVP via this link if you would like to register to attend the meeting in person or have access to the meeting livestreams and on-demand content to cover the meeting remotely

###

Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to the principle that knowledge conquers cancer. Together with the Association for Clinical Oncology, ASCO represents nearly 50,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of high quality, equitable patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. Conquer Cancer, the ASCO Foundation, supports ASCO by funding groundbreaking research and education across cancer's full continuum. Learn more at www.ASCO.org, explore patient education resources at www.Cancer.Net, and follow us on Facebook, Twitter, LinkedIn, Instagram, and YouTube.